Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials

por Yu, Bin, Morales, Javier F., O'Rourke, Sara M., Tatsuno, Gwen P., Berman, Phillip W.
Publicado 2012

Phylodynamics of HIV-1 from a Phase-III AIDS Vaccine Trial in North America

por Pérez-Losada, Marcos, Jobes, David V., Sinangil, Faruk, Crandall, Keith A., Posada, David, Berman, Phillip W.
Publicado 2010

Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial

por Pérez-Losada, Marcos, Posada, David, Arenas, Miguel, Jobes, David V, Sinangil, Faruk, Berman, Phillip W, Crandall, Keith A
Publicado 2009

Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand

por Pérez-Losada, Marcos, Jobes, David V., Sinangil, Faruk, Crandall, Keith A., Arenas, Miguel, Posada, David, Berman, Phillip W.
Publicado 2011

Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding

por Nakamura, Gerald R., Fonseca, Dora P. A. J., O'Rourke, Sara M., Vollrath, Aaron L., Berman, Phillip W.
Publicado 2012

Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies

por Smith, Douglas H., Winters-Digiacinto, Peggy, Mitiku, Misrach, O'Rourke, Sara, Sinangil, Faruk, Wrin, Terri, Montefiori, David C., Berman, Phillip W.
Publicado 2010

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies

por Doran, Rachel C., Tatsuno, Gwen P., O’Rourke, Sara M., Yu, Bin, Alexander, David L., Mesa, Kathryn A., Berman, Phillip W.
Publicado 2018

Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure

por Aiyegbo, Mohammed S., Shmelkov, Evgeny, Dominguez, Lorenzo, Goger, Michael, Battacharya, Shibani, deCamp, Allan C., Gilbert, Peter B., Berman, Phillip W., Cardozo, Timothy
Publicado 2017

Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens

por Li, Sophia W., Wright, Meredith, Healey, John F., Hutchinson, Jennie M., O’Rourke, Sara, Mesa, Kathryn A., Lollar, Pete, Berman, Phillip W.
Publicado 2020

Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production

por O’Rourke, Sara M., Byrne, Gabriel, Tatsuno, Gwen, Wright, Meredith, Yu, Bin, Mesa, Kathryn A., Doran, Rachel C., Alexander, David, Berman, Phillip W.
Publicado 2018

CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation

por Byrne, Gabriel, O’Rourke, Sara M., Alexander, David L., Yu, Bin, Doran, Rachel C., Wright, Meredith, Chen, Qiushi, Azadi, Parastoo, Berman, Phillip W.
Publicado 2018

Glycans Flanking the Hypervariable Connecting Peptide between the A and B Strands of the V1/V2 Domain of HIV-1 gp120 Confer Resistance to Antibodies That Neutralize CRF01_AE Viruse...

por O’Rourke, Sara M., Sutthent, Ruengpung, Phung, Pham, Mesa, Kathryn A., Frigon, Normand L., To, Briana, Horthongkham, Navin, Limoli, Kay, Wrin, Terri, Berman, Phillip W.
Publicado 2015

Development of a Stable MGAT1(−) CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies

por Doran, Rachel C., Yu, Bin, Wright, Meredith, O'Rourke, Sara M., Yin, Lu, Richardson, Jennie M., Byrne, Gabriel, Mesa, Kathryn A., Berman, Phillip W.
Publicado 2018

Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120

por Doran, Rachel C., Morales, Javier F., To, Briana, Morin, Trevor J., Theolis Jr., Richard, O’Rourke, Sara M., Yu, Bin, Mesa, Kathryn A., Berman, Phillip W.
Publicado 2014

Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies

por Hutchinson, Jennie M., Mesa, Kathryn A., Alexander, David L., Yu, Bin, O'Rourke, Sara M., Limoli, Kay L., Wrin, Terri, Deeks, Steven G., Berman, Phillip W.
Publicado 2019

Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens

por Mesa, Kathryn A., Yu, Bin, Wrin, Terri, Petropoulos, Christos J., Pogson, Grant H., Alexander, David L., Perez, Gerardo, O’Rourke, Sara M., Sinangil, Faruk, Robinson, Joseph, Conant, Marcus A., Berman, Phillip W.
Publicado 2019

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144

por Perez, Lautaro G., Martinez, David R., deCamp, Allan C., Pinter, Abraham, Berman, Phillip W., Francis, Donald, Sinangil, Faruk, Lee, Carter, Greene, Kelli, Gao, Hongmei, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, O’Connell, Robert J., Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Gilbert, Peter, Montefiori, David C.
Publicado 2017

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

por Yates, Nicole L., deCamp, Allan C., Korber, Bette T., Liao, Hua-Xin, Irene, Carmela, Pinter, Abraham, Peacock, James, Harris, Linda J., Sawant, Sheetal, Hraber, Peter, Shen, Xiaoying, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayapan, Sorachai, Berman, Phillip W., Robb, Merlin L., Pantaleo, Giuseppe, Zolla-Pazner, Susan, Haynes, Barton F., Alam, S. Munir, Montefiori, David C., Tomaras, Georgia D.
Publicado 2018

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

por Gilbert, Peter B., Excler, Jean-Louis, Tomaras, Georgia D., Carpp, Lindsay N., Haynes, Barton F., Liao, Hua-Xin, Montefiori, David C., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Kijak, Gustavo H., Tovanabutra, Sodsai, Francis, Donald P., Lee, Carter, Sinangil, Faruk, Berman, Phillip W., Premsri, Nakorn, Kunasol, Prayura, O’Connell, Robert J., Michael, Nelson L., Robb, Merlin L., Morrow, Rhoda, Corey, Lawrence, Kim, Jerome H.
Publicado 2017

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

por Gottardo, Raphael, Bailer, Robert T., Korber, Bette T., Gnanakaran, S., Phillips, Joshua, Shen, Xiaoying, Tomaras, Georgia D., Turk, Ellen, Imholte, Gregory, Eckler, Larry, Wenschuh, Holger, Zerweck, Johannes, Greene, Kelli, Gao, Hongmei, Berman, Phillip W., Francis, Donald, Sinangil, Faruk, Lee, Carter, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Zolla-Pazner, Susan, Haynes, Barton F., Mascola, John R., Self, Steve, Gilbert, Peter, Montefiori, David C.
Publicado 2013